UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000026866
Receipt No. R000030829
Scientific Title Impact on immune function by ingesting Natto
Date of disclosure of the study information 2017/04/05
Last modified on 2017/04/05

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Impact on immune function by ingesting Natto
Acronym Impact on immune function by ingesting Natto
Scientific Title Impact on immune function by ingesting Natto
Scientific Title:Acronym Impact on immune function by ingesting Natto
Region
Japan

Condition
Condition Healthy Adult
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Evaluate the influence on immune function when feeding Natto for 8 weeks, for middle-aged and elderly subjects whose immune function tends to decline.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Secretory immunoglobulin A (S-IgA)
Key secondary outcomes Tiredness/Feeling (VAS)

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Food
Interventions/Control_1 Natto
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
50 years-old <=
Age-upper limit
64 years-old >=
Gender Male and Female
Key inclusion criteria Healthy men and women of ages 50 to 64 years old
Key exclusion criteria 1. Persons who have symptoms of hay fever and perennial allergic rhinitis
2. Persons who have diseases in the oral cavity such as periodontal disease or dry mice
3. Person who has heart disease
4. Person who take warfarin
5. Person who has a history of diabetes, liver disease, kidney disease, gastrointestinal disease, peripheral vascular disease, other severe disease
6. Persons who show impaired cardiopulmonary function
7. Persons who liver function and renal function test values show abnormalities
8. Persons who have had surgery on the gastrointestinal tract
9. Currently, those with a disorder under treatment
10. Persons who have food or drug allergy
11. Persons who do intense sports or are on a diet
12. Persons who are taking health foods, quasi medical items, medicines (including OTC, prescription medicine) containing ingredients contained in the test food
13. Persons who consume excess alcohol or can not abstinence from the day before the test until the day
14. Persons who are pregnant, or persons who are planning to become pregnant or breastfeeding during the study period
15. Persons who are participating in the other study or planning to participate during the study period
16. Persons who judged inappropriate by the study responsible doctor for other reasons
Target sample size 18

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Naoki Miura
Organization Miura Clinic, Medical Corporation Kanonkai
Division name Internal Medicine
Zip code
Address 9F Higashitenma Bldg.,1-7-17 Higashitenma, Kita-ku, Osaka-shi, Osaka, Japan
TEL 06-6135-5200
Email info@miura-cl.jp

Public contact
Name of contact person
1st name
Middle name
Last name Makoto Terashima
Organization Oneness Support Co., Ltd.
Division name Clinical trial Division
Zip code
Address 9F Higashitenma Bldg.,1-7-17 Higashitenma, Kita-ku, Osaka-shi, Osaka, Japan
TEL 06-4801-8917
Homepage URL
Email mterashima@miura-cl.jp

Sponsor
Institute Takanofoods Co., Ltd.
Institute
Department

Funding Source
Organization Takanofoods Co., Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor Miura Clinic, Medical Corporation Kanonkai
Oneness Support Co., Ltd.
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2017 Year 04 Month 05 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2017 Year 02 Month 23 Day
Date of IRB
Anticipated trial start date
2017 Year 04 Month 10 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2017 Year 04 Month 05 Day
Last modified on
2017 Year 04 Month 05 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030829

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.